Roche’s Kadcyla wins NICE backing in early breast cancer use

The antibody-drug conjugate Kadcyla that targets HER2-positive cancer did not have any problems with England's National Health Service watch dog on any drugs that cost over $50,000. Previously, England rejected Kadcyla, which was approved for pateints with metastatic breast cancer because the drug only offers you 6 months to 1 year survival yet costs close to $90,000 per treatment cycle. That is outrageous! Roche had to make a deal to lower the cost and the details are confidential. Kadcyla is now approved for early treatment of breast cancer. This time Roche must have made a better deal right away with England as there was no problem this time around. Read more here.